Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus Anlotinib in HER2-negative advanced breast cancer
NCT06678230Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in breast cancer, sponsored by The First Hospital of Jilin University. Primary endpoint: Progression-Free Survival up to 33 months. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06678230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678230.